Canagliflozin Delays Aging of HUVECs Induced by Palmitic Acid via the ROS/p38/JNK Pathway
Antioxidants · 30.03.2023 · 12 (4) · 838
DOI: 10.3390/antiox12040838 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antioxidants, online erschienen am 30.03.2023. Verfasst von Wenhui Hao und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemical Oncogenomics, Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Science and Technology Program, The State Key Labora-tory of Chemical Oncogenomics, Shenzhen International Graduate School, Tsinghua University, The State Key Laboratory of Chemical Oncogenomics, Shenzhen International Graduate School, Tsinghua University.
Abstract (Originalsprache)
Vascular aging is an important factor contributing to cardiovascular diseases, such as hypertension and atherosclerosis. Hyperlipidemia or fatty accumulation may play an important role in vascular aging and cardiovascular diseases. Canagliflozin (CAN), a sodium-glucose cotransporter inhibitor, can exert a cardiovascular protection effect that is likely independent of its hypoglycemic activities; however, the exact mechanisms remain undetermined. We hypothesized that CAN might have protective effects on blood vessels by regulating vascular aging induced by hyperlipidemia or fatty accumulation in blood vessel walls. In this study, which was undertaken on the basis of aging and inflammation, we investigated the protective effects and mechanisms of CAN in human umbilical vein endothelial cells induced by palmitic acid. We found that CAN could delay vascular aging, reduce the secretion of the senescence-associated secretory phenotype (SASP) and protect DNA from damage, as well as exerting an effect on the cell cycle of senescent cells. These actions likely occur through the attenuation of the excess reactive oxygen species (ROS) produced in vascular endothelial cells and/or down-regulation of the p38/JNK signaling pathway. In summary, our study revealed a new role for CAN as one of the sodium-dependent glucose transporter 2 inhibitors in delaying lipotoxicity-induced vascular aging by targeting the ROS/p38/JNK pathway, giving new medicinal value to CAN and providing novel therapeutic ideas for delaying vascular aging in patients with dyslipidemia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Chemical Oncogenomics, Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China.
- Shenzhen Key Laboratory of Health Science and Technology, Institute of Biopharmaceutical and Health, Tsinghua University, Shenzhen 518055, China.
- Open FIESTA Center, Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China.
- Institute for Ocean Engineering, Shenzhen International Graduate School, Tsinghua University, Shenzhen 518055, China.
ORCID-Profile: Fang Wan, Jin Zhou, Yaou Zhang, Weidong Xie
Förderung
- Shenzhen Science and Technology Program
- The State Key Labora-tory of Chemical Oncogenomics, Shenzhen International Graduate School, Tsinghua University
- The State Key Laboratory of Chemical Oncogenomics, Shenzhen International Graduate School, Tsinghua University
Zitieren
APA
Hao, W., Shan, W., Wan, F., Luo, J., Niu, Y., Zhou, J., Zhang, Y., Xu, N., & Xie, W. (2023). Canagliflozin Delays Aging of HUVECs Induced by Palmitic Acid via the ROS/p38/JNK Pathway. Antioxidants, 12(4), 838. https://doi.org/10.3390/antiox12040838
Vancouver
Hao W, Shan W, Wan F, Luo J, Niu Y, Zhou J, et al. Canagliflozin Delays Aging of HUVECs Induced by Palmitic Acid via the ROS/p38/JNK Pathway. Antioxidants. 2023;12(4):838. doi:10.3390/antiox12040838
BibTeX
@article{Hao2023,
author = {Hao, Wenhui and Shan, Wenjie and Wan, Fang and Luo, Jingyi and Niu, Yaoyun and Zhou, Jin and Zhang, Yaou and Xu, Naihan and Xie, Weidong},
title = {Canagliflozin Delays Aging of HUVECs Induced by Palmitic Acid via the ROS/p38/JNK Pathway},
journal = {Antioxidants},
year = {2023},
volume = {12},
number = {4},
pages = {838},
doi = {10.3390/antiox12040838}
}
EUVIMED